Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Piramal Pharma Limited (NSE: PPLPHARMA), ISIN INE0DK501011 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
PPLPHARMA last traded at ₹213.05 (+1.14%), with a 52-week range of ₹132.50 to ₹231.85 (as of 23 Sep 2026).
Shareholding as of Jun 2026: promoters 34.80%, FIIs 12.52%, DIIs 14.57%, mutual funds 13.18%.
EquiSense Score (ECS): 74/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.